Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
REPL logo REPL
Upturn stock ratingUpturn stock rating
REPL logo

Replimune Group Inc (REPL)

Upturn stock ratingUpturn stock rating
$5.38
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: REPL (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $4.86

1 Year Target Price $4.86

Analysts Price Target For last 52 week
$4.86 Target price
52w Low $2.68
Current$5.38
52w High $17

Analysis of Past Performance

Type Stock
Historic Profit -69.96%
Avg. Invested days 42
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 421.50M USD
Price to earnings Ratio -
1Y Target Price 4.86
Price to earnings Ratio -
1Y Target Price 4.86
Volume (30-day avg) 8
Beta 0.67
52 Weeks Range 2.68 - 17.00
Updated Date 08/29/2025
52 Weeks Range 2.68 - 17.00
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.25

Earnings Date

Report Date 2025-08-06
When Before Market
Estimate -0.8429
Actual -0.95

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -36.45%
Return on Equity (TTM) -73.44%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 92927451
Price to Sales(TTM) -
Enterprise Value 92927451
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.24
Shares Outstanding 78055800
Shares Floating 49983061
Shares Outstanding 78055800
Shares Floating 49983061
Percent Insiders 2
Percent Institutions 104.89

ai summary icon Upturn AI SWOT

Replimune Group Inc

stock logo

Company Overview

overview logo History and Background

Replimune Group Inc. was founded in 2015. It is a biotechnology company focused on developing oncolytic immunotherapies to treat cancer. It went public in 2018. Replimune's approach involves using genetically modified viruses to selectively replicate within tumors, causing tumor cell death and stimulating an immune response against the cancer.

business area logo Core Business Areas

  • Oncolytic Immunotherapy Development: Replimune's core business is the research and development of oncolytic immunotherapies, specifically engineered viruses that selectively infect and destroy cancer cells while stimulating an anti-tumor immune response.

leadership logo Leadership and Structure

Philip Astrow is the Chief Executive Officer. The company has a typical organizational structure for a biotechnology firm, with departments focused on research, clinical development, manufacturing, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • RP1 (vusolimogene oderparepvec): RP1 is Replimune's lead product candidate, an oncolytic virus being developed for various solid tumors, including cutaneous squamous cell carcinoma (CSCC), melanoma, and non-melanoma skin cancers. Market share data is not yet applicable as it is still in clinical development. Key competitors are companies developing similar oncolytic viruses or other immunotherapies, such as Amgen (T-VEC) and other companies with checkpoint inhibitors like Merck (Keytruda).

Market Dynamics

industry overview logo Industry Overview

The oncolytic virus therapy market is a growing segment of the broader immuno-oncology market. It is driven by the need for more effective and targeted cancer treatments with fewer side effects. The industry is characterized by innovation and increasing investment in research and development.

Positioning

Replimune is positioned as a leader in the oncolytic virus therapy space, with a focus on developing potent and immunogenic oncolytic viruses. Its competitive advantages include its proprietary Immulytic platform and its focus on combination therapies.

Total Addressable Market (TAM)

The overall immuno-oncology market is projected to reach hundreds of billions of dollars. Replimune is positioned to capture a portion of this TAM through its oncolytic virus therapies, focusing initially on specific tumor types with high unmet needs. The specific TAM for RP1 and other pipeline products depends on regulatory approvals and market penetration.

Upturn SWOT Analysis

Strengths

  • Proprietary Immulytic platform
  • Strong preclinical and clinical data for RP1
  • Experienced management team
  • Focus on combination therapies

Weaknesses

  • Reliance on a single lead product candidate (RP1)
  • High cash burn rate
  • Dependence on clinical trial success
  • Manufacturing complexity

Opportunities

  • Potential for RP1 to become a blockbuster drug
  • Expansion of pipeline with new oncolytic virus candidates
  • Partnerships with pharmaceutical companies
  • Expansion into new cancer indications

Threats

  • Clinical trial failures
  • Competition from other oncolytic viruses and immunotherapies
  • Regulatory hurdles
  • Manufacturing challenges
  • Adverse events related to the treatment

Competitors and Market Share

competitor logo Key Competitors

  • AMGN
  • MRK
  • BMY

Competitive Landscape

Replimune competes with other companies developing oncolytic viruses and immunotherapies. Its advantages include its proprietary Immulytic platform and focus on combination therapies. Disadvantages include its reliance on a single lead product candidate and high cash burn rate. Amgen's T-VEC is an approved oncolytic virus therapy for melanoma, and companies like Merck and Bristol Myers Squibb have established checkpoint inhibitors.

Growth Trajectory and Initiatives

Historical Growth: Growth has been primarily in terms of clinical development and pipeline expansion, rather than revenue. The company has progressed RP1 through multiple clinical trials.

Future Projections: Future growth depends on the successful development and commercialization of RP1 and other pipeline candidates. Analyst estimates vary widely depending on the perceived probability of success.

Recent Initiatives: Recent initiatives include advancing RP1 in multiple clinical trials, expanding the pipeline with new oncolytic virus candidates, and pursuing partnerships with pharmaceutical companies.

Summary

Replimune is a clinical-stage biotech company with a promising oncolytic virus platform. Their lead product, RP1, shows potential, but the company faces risks common to drug development, including clinical trial success and regulatory approval. The company's high cash burn rate needs to be managed carefully, and success hinges on data. Overall, Replimune has potential but has a long way to go.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Replimune Group Inc. SEC filings
  • Analyst reports
  • Company website
  • Industry publications

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be entirely accurate or complete. Investment decisions should be made based on individual due diligence and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Replimune Group Inc

Exchange NASDAQ
Headquaters Woburn, MA, United States
IPO Launch date 2018-07-20
CEO & Director Dr. Sushil Patel Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 479
Full time employees 479

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.